Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120 , HER2 and TRPS1
Histopathology · 2026-08 · 89 (2) · 338-346
DOI: 10.1111/his.70172 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Histopathology, online erschienen am 05.05.2026. Verfasst von Busra Yaprak Bayrak und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Membrane Proteins. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Plasmacytoid urothelial carcinoma (PUC) is an aggressive morphological subtype characterized by discohesive single‐cell infiltration and frequent loss of epithelial adhesion. Although p63 is widely regarded as a reliable urothelial lineage marker in conventional urothelial carcinoma, its expression may be reduced or absent in plasmacytoid tumours, creating an important diagnostic pitfall. This multi‐institutional study aimed to characterize the clinicopathological and immunohistochemical profile of PUC, with particular emphasis on p63 immunoreactivity and its relationship to adhesion‐related markers and other diagnostically relevant immunophenotypes. Methods and results A total of 93 cases initially diagnosed as PUC were retrospectively reviewed across multiple centres. After histopathological re‐evaluation, 70 confirmed cases were included. Immunohistochemical analysis was performed for p63, e‐cadherin, p120 catenin, TRPS1, HER2/Neu . The cohort comprised 70 patients with a median age of 66.5 years (IQR, 59.8–72.0) and a strong male predominance of 85.7% (60/70). Most specimens were obtained from transurethral resections (64.3%, 45/70) and radical cystectomy specimens (34.3%, 24/70). The median tumour size was 3.0 cm (IQR, 1.0–5.0), and the median proportion of plasmacytoid differentiation was 80% (IQR, 20–100). Morphologically, tumours were classified as classic plasmacytoid in 65.7% (46/70), pleomorphic in 22.9% (16/70) and desmoplastic in 11.4% (8/70). Concurrent variant histology was identified in 21.4% (15/70), most commonly micropapillary (12.9%, 9/70) and sarcomatoid (7.1%, 5/70) components. Lymphovascular invasion was present in 51.4% (36/70), and concomitant carcinoma in situ was detected in 35.7% (25/70). Immunohistochemically, p63 expression was retained in only 10.0% of tumours (7/70). HER2 membranous overexpression was observed in 58.6% (41/70), while loss of E‐cadherin expression was highly prevalent (84.3%, 59/70). Aberrant p120 catenin expression was common, with cytoplasmic localization in 72.9% (51/70) and complete loss in 17.1% (12/70). TRPS1 immunostaining was available in 54 tumours and was negative in 92.6% of evaluable cases (50/54).
Conclusion
PUC demonstrates a distinctive immunophenotype characterized by frequent loss of p63 and disruption of the e‐cadherin/p120 adhesion complex. Recognition of p63 attenuation, together with adhesion‐related markers and HER2 status, provides a useful diagnostic framework for distinguishing this aggressive subtype from conventional urothelial carcinoma and its mimickers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, Kocaeli University, Kocaeli, Turkey.
- Department of Pathology, School of Medicine, Hacettepe University, Ankara, Turkey.
- Department of Pathology, Kutahya Evliya Celebi Research and Training Hospital, Kutahya, Turkey.
- Department of Pathology, Memorial Sisli Hospitals Group, Istanbul, Turkey.
- Department of Pathology, School of Medicine, Bezmialem Vakıf University, Istanbul, Turkey.
- Department of Pathology, Ankara Etlik City Hospital, Ankara, Turkey.
ORCID-Profile: Busra Yaprak Bayrak, Kemal Kosemehmetoglu, Busra Ozbek, Sercan Simsek, Murat Oktay, Ganime Coban, Dilara Irem Arslan Kahraman, Egemen Akıncıoglu, Melek Buyukgok, Selin Colak, Hatice Nese Dogan, Burak Gurel, Selva Kabul, Kerem Karaca, Elif Ozsagir, Ece Ozturk, Havva Serap Toru, Gupse Turan, Nazif Alperen Yıldırım, Ozlem Nur Yıldız, Yasemin Yuyucu Karabulut, Liang Cheng, Mahmut Akgul
Zitieren
APA
Yaprak Bayrak, B., Kosemehmetoglu, K., Ozbek, B., Simsek, S., Oktay, M., Coban, G., Arslan Kahraman, D. I., Akıncıoglu, E., Buyukgok, M., Colak, S., Dogan, H. N., Gurel, B., Kabul, S., Karaca, K., Ozsagir, E., Ozturk, E., Toru, H. S., Turan, G., Yıldırım, N. A., …, & Akgul, M. (2026). Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120 , HER2 and TRPS1. Histopathology, 89(2), 338-346. https://doi.org/10.1111/his.70172
Vancouver
Yaprak Bayrak B, Kosemehmetoglu K, Ozbek B, Simsek S, Oktay M, Coban G, et al. Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120 , HER2 and TRPS1. Histopathology. 2026;89(2):338-346. doi:10.1111/his.70172
BibTeX
@article{YaprakBayrak2026,
author = {Yaprak Bayrak, Busra and Kosemehmetoglu, Kemal and Ozbek, Busra and Simsek, Sercan and Oktay, Murat and Coban, Ganime and Arslan Kahraman, Dilara Irem and Akıncıoglu, Egemen and Buyukgok, Melek and Colak, Selin and Dogan, Hatice Nese and Gurel, Burak and Kabul, Selva and Karaca, Kerem and Ozsagir, Elif and Ozturk, Ece and Toru, Havva Serap and Turan, Gupse and Yıldırım, Nazif Alperen and Yıldız, Ozlem Nur and Karabulut, Yasemin Yuyucu and Cheng, Liang and Akgul, Mahmut},
title = {Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120 , HER2 and TRPS1},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {2},
pages = {338--346},
doi = {10.1111/his.70172}
}
EUVIMED